NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BROOKS · data 2026-10-31
Brooks Laboratories Limited
In plain words
Price: 46.7% below its 52-week high of ₹113.69.
Delivery: 54.1% of traded shares were kept for delivery over the last 10 sessions, against 56.9% over the last 60.
Latest results: a net loss of ₹9 cr for the quarter ended Dec 2022.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹83 cr |
| Net profit (last 12 months) | ₹13 cr |
| Sales growth, 3 years (yearly) | 10.9% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 52.6% (unchanged in a year), pledged 0.0%, institutions 10.5%.
P/E 13.5, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 22.3%, ROCE 4.8%, operating margin 5.0%: how much profit it earns on the money it uses.
Debt/equity 0.07, Profit growth — and sales growth 10.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (22.3%).
- Reported a loss in the latest quarter.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY23)
BROOKS Q3 FY23 results (consolidated figures, as filed on NSE).
Revenue was ₹15.3 crore.
Net loss was ₹9.48 crore.
Operating margin was 55.9%.
EPS was -₹2.03.
BROOKS के Q3 FY23 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹15.3 करोड़।
शुद्ध घाटा: ₹9.48 करोड़।
ऑपरेटिंग मार्जिन: 55.9%।
EPS: -₹2.03।
BROOKSના Q3 FY23 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹15.3 કરોડ.
ચોખ્ખી ખોટ: ₹9.48 કરોડ.
ઓપરેટિંગ માર્જિન: 55.9%.
EPS: -₹2.03.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹0.14 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal
- 8 Oct 26Deal Bulk deal: AMIT KUMAR JAIN sold ₹0.14 cr +19.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2022 | ₹15 cr | ₹-9 cr | — | -55.9% | -2.03 |
Shareholding trend
| Holder | Sept 2026 | Mar 2026 | Sept 2025 |
|---|---|---|---|
| Promoters | 52.62% | 52.62% | 52.62% |
| Foreign institutions (FII) | 0.04% | 0.17% | 0.01% |
| Domestic institutions (DII) | 10.50% | 10.38% | 10.38% |
| Mutual funds | 9.90% | 9.90% | 9.90% |
| Retail investors | 18.52% | 17.31% | 17.09% |
| Number of shareholders | 11,253 | 10,741 | 10,078 |
Common questions
What was Brooks Laboratories Limited's latest quarterly profit?
Brooks Laboratories Limited reported a net loss of ₹9 cr for the quarter ended Dec 2022, on revenue of ₹15 cr.
How much do promoters hold in Brooks Laboratories Limited?
Promoters held 52.62% of Brooks Laboratories Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Brooks Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0.07, which is very low.
What is Brooks Laboratories Limited's P/E ratio?
About 13.5, based on the last 12 months' earnings and a price of ₹60.56 (data 2026-10-31).
What is the 52-week high and low of Brooks Laboratories Limited?
The 52-week high is ₹113.69 and the 52-week low is ₹36.3.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Brooks Laboratories Limited | ₹60.56 | ₹179 cr | 13.5 | — | 22.3% | 4.8% | 0.07 | -43.3% |
| Accretion Pharmaceuticals Ltd. | ₹190.05 | ₹211 cr | 21.9 | 3.9 | 27.6% | 38.3% | 0.23 | +234.9% |
| Nectar Lifesciences Ltd. | ₹10.2 | ₹200 cr | — | — | -7.5% | -0.9% | 0 | -38.3% |
| Medico Remedies Ltd. | ₹18.61 | ₹155 cr | 11.2 | — | 19% | 20.4% | 0.26 | -61.3% |
| Curis Lifesciences Limited | ₹180 | ₹146 cr | 21.2 | 3.1 | 21.7% | 26.6% | 0.46 | +23.2% |
| Quest Laboratories Ltd. | ₹82 | ₹134 cr | 9 | 1.4 | 16.7% | 19.3% | 0.08 | -6.8% |
Compare BROOKS with ACCPL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BROOKS in NSE Scanner →